Long-Term Evaluation of the Use of the Transdermal Contraceptive Patch in Adolescents

The transdermal contraceptive patch, Ortho Evra™, was approved in December 2001 and released on the market in June 2002. In this study, we reviewed clinical data of young women who started the patch between June 2002 and December 2003 in the adolescent medicine clinic at a university-based outpatient center. A total of 62 patients started the patch in that period and two of them were lost to follow-up. Mean age of patients was 17.9 years and mean length of use was 10 cycles. Only 10 patients (16.7%) discontinued use. Reasons for discontinuation were moderate to severe skin irritation (3 patients, 5%), complete detachment (3 patients, 5%), and economic reasons (4 patients, 6.7%). Compliance was excellent overall and the side-effects profile was good. No pregnancies occurred during this period. These results confirmed that the transdermal contraceptive patch is easy to use and an effective method of birth control that may be better tolerated by young women. It also seemed to improve contraceptive compliance in this population.

[1]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.

[2]  S. Riggs,et al.  Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. , 2005, Journal of pediatric and adolescent gynecology.

[3]  Mark L Rubinstein,et al.  An evaluation of the use of the transdermal contraceptive patch in adolescents. , 2004, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[4]  B. Sibai,et al.  A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). , 2002, Fertility and sterility.

[5]  A. Fisher,et al.  Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. , 2002, Fertility and sterility.

[6]  A. Fisher,et al.  Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. , 2002, Fertility and sterility.

[7]  J. Natarajan,et al.  Pharmacokinetic overview of Ortho Evra/Evra. , 2002, Fertility and sterility.

[8]  G. Anderson,et al.  Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. , 2002, British journal of clinical pharmacology.

[9]  A. Fisher,et al.  Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. , 2001, Fertility and sterility.

[10]  A. Fisher,et al.  Efficacy and Safety of a Transdermal Contraceptive System , 2001, Obstetrics and gynecology.

[11]  A. Fisher,et al.  Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. , 2001, JAMA.

[12]  M. Chacko,et al.  Assessment of oral contraceptive pill continuation in young women. , 1999, Journal of pediatric and adolescent gynecology.

[13]  J. Darroch,et al.  Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. , 1999, Family planning perspectives.

[14]  S. Henshaw.  Unintended pregnancy in the United States. , 1998, Family planning perspectives.